Money
Briefing: From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here
Strategic angle: Piper Sandler analysts project a significant increase in CRSP's stock value, highlighting key factors driving this optimism.
editorial-staff
1 min read
Updated 25 days ago
Piper Sandler has established a target price of $110 for CRSP, suggesting significant upside potential from the current trading price of approximately $49.
The analysts attribute this optimistic projection to CRSP's strong product pipeline and favorable market conditions, which could enhance throughput and operational capacity.
This assessment reflects a strategic outlook on CRSP's ability to leverage its assets effectively within the biopharmaceutical sector.